Vagus nerve stimulation

Ultrasound Neuromodulation Shows Promise to Treat Pulmonary Hypertension, Feinstein Institutes Research

Retrieved on: 
Tuesday, May 7, 2024
Health, Science, Radiology, Research, Cardiology, Brain, Cancer, Inflammation, Crohn's disease, Biomedical engineering, Cell, Pulmonary hypertension, American Heart Association, Woman, Blood, Vagus nerve stimulation, Autonomic nervous system, Inflammatory Bowel Diseases, Disease, Heart, Vagus nerve, Death, Diabetes, Interface (computing), Neuroscience, MD, PAH, Doctor of Philosophy, GE Research, Constriction, Spleen, VNS, Human, Sensation, Pressure, Circulation Research, Patient, Arthritis, Nervous system, Molecular medicine, Reflex, Medical research, Multimedia, Paralysis, Biomarker, Credit, Orthostatic hypertension, Heart failure, Medical imaging

Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).

Key Points: 
  • Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).
  • View the full release here: https://www.businesswire.com/news/home/20240507538578/en/
    Feinstein Institutes’ Dr. Stavros Zanos is the senior author on the new bioelectronic medicine ultrasound paper.
  • The research adds to the growing scientific evidence of bioelectronic medicine and neuromodulation as an effective therapy to treat diseases with an inflammatory component.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Vagus nerve activation of the spleen shows promise to treat infections, Feinstein Institutes research

Retrieved on: 
Friday, April 26, 2024
Biotechnology, Managed Care, Health, General Health, Pharmaceutical, Health Technology, Other Science, Research, Hospitals, Science, Clinical Trials, Diamond, Autoantibody, Cancer, Bangladesh Technical Education Board, Inflammation, Biomedical engineering, National academy, National Academy of Sciences, Mouse, Crohn's disease, Pulmonary hypertension, Map, Science Advances, Vagus nerve stimulation, Inflammatory Bowel Diseases, Diabetes, Interface (computing), Neuroscience, Acetylcholine, Doctor of Philosophy, Spleen, VNS, DRS, Disease, Anatomy, Human, Sensation, Autoimmune disease, Nervous system, Arthritis, Molecular medicine, Physiology, Medicine, Immunology, Medical research, Multimedia, Lupus, Immune system, Antibody, Paralysis, Immunity, Credit, Autoimmunity, Sepsis, Vagus nerve, Vaccine

New research published in Science Advances by The Feinstein Institutes for Medical Research scientists shows that activation of the vagus nerve triggers the spleen, thereby regulating the production of antibodies.

Key Points: 
  • New research published in Science Advances by The Feinstein Institutes for Medical Research scientists shows that activation of the vagus nerve triggers the spleen, thereby regulating the production of antibodies.
  • This research highlights how the nervous system regulates immunity and suggests potential for non-pharmalogical, vagus nerve modulation to treat a variety of diseases, like lupus and sepsis.
  • Dr. Zanos’s research focus is on understanding the anatomy and physiology of the vagus nerve and the effects vagus nerve stimulation has in inflammation and cardiovascular diseases.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Tivic Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Medical Devices, Biometrics, Health, Health Technology, Research, Congestion, VNS, GHP, Telephone, Vagus nerve stimulation, Medical device, Security (finance), Bank statement, System, Marketing, FDA, Advertising, Cryptocurrency

Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023.

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023.
  • “2023 was a year for both streamlining our commercial business and defining new opportunities for value creation,” stated Jennifer Ernst, CEO of Tivic.
  • Research and development expenses were approximately $1.7M for each of the years ended December 31, 2023 and December 31, 2022.
  • Management will host a webcast/conference call on Monday, March 25, 2024, at 1:30 PM PT / 4:30 PM ET to discuss the company’s year-end 2023 financial results and provide a business update, including comments on research directions undertaken in 2023.

Minneapolis Psychiatry Clinic Adds Vagus Nerve Stimulation as Non-Drug Therapy for Severe Depression

Retrieved on: 
Wednesday, March 20, 2024
Mental Health, Surgery, Medical Devices, Alternative Medicine, Health, Vagus nerve, Deep brain stimulation, Depression, DSM-IV codes, Brain, VNS, LivaNova, Vagus nerve stimulation, Patient, TMS, Mental health, Bipolar disorder, Skin, Ketamine, Transcranial magnetic stimulation, Medicare, FDA, CMS

Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.

Key Points: 
  • Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.
  • VNS has a 70% success rate when used for treatment resistant depression, meaning the patient hasn’t responded to traditional antidepressants.
  • VNS stimulates the vagus nerve, triggering its natural process of sending electrical pulses to the parts of the brain that control mood.
  • For more information about Vagus Nerve Stimulation and what to expect, visit Advanced Brain and Body Clinic’s VNS page .

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024
Pulse, Growth, Market development, Research, Abbott Laboratories, Ageing, Tetraplegia, Prevalence, Spinal cord stimulator, Deep brain stimulation, Vagus nerve stimulation, DSM-IV codes, Investment, Parkinson's disease, LivaNova, Competition, Epilepsy, Alzheimer's disease, Boston Scientific, Pharmaceutical industry

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the neuromodulation market across varied regions.

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024
Pulse, Growth, Market development, Research, Abbott Laboratories, Ageing, Tetraplegia, Prevalence, Spinal cord stimulator, Deep brain stimulation, Vagus nerve stimulation, DSM-IV codes, Investment, Parkinson's disease, Epilepsy, Competition, Alzheimer's disease, Boston Scientific, Pharmaceutical industry

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • In 2022, internal neuromodulation dominated the global neuromodulation market.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.

Pulsetto Unveils Groundbreaking Vagus Nerve Stimulation Device at CES

Retrieved on: 
Thursday, January 4, 2024
Cluster, Pain management, Philosophy, Cluster headache, Pain, Migraine, Periodicity, Neurostimulation, Vagus nerve stimulation, Sleep, Vagus nerve, CES, VNS, Relaxation, Neck

Pulsetto, a leader in Vagus Nerve Stimulation technology, is showcasing at CES its unique dual-technology system and personalized app designed to alleviate stress, reduce anxiety, improve sleep, and manage pain, exemplifying a practical and everyday approach to enhancing mental wellness.

Key Points: 
  • Klaipeda County, Lithuania--(Newsfile Corp. - January 4, 2024) - Pulsetto is set to showcase at CES in Las Vegas, bringing its effective Vagus Nerve Stimulation (VNS) device into the spotlight.
  • A pivotal moment came when he encountered an article about vagus nerve stimulation, sparking the idea for Pulsetto.
  • This device innovatively activates the vagus nerve, a key player in regulating stress responses in the body.
  • On this note, Pulsetto invites all CES attendees to booth 8867 for a hands-on experience with its transformative Vagus Nerve Stimulation device.

Neurostimulation Technology and Global Markets Report 2023: 2020-2022 Data, Estimates for 2023, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 20, 2023
Medical Devices, Health, Quality of life, Obstructive sleep apnea, Essential tremor, DSM-IV codes, Epilepsy, Tremor, Chronic pain, Neuron, Brain, System, Projection, Spinal cord stimulator, Tic disorder, Incontinence, Parkinson's disease, Obesity, Tinnitus, Nervous system, Deep brain stimulation, Vagus nerve stimulation, Dystonia, Growth, Transcranial magnetic stimulation, Medical device

This report provides a comprehensive study of the global market for neurostimulation technologies and devices.

Key Points: 
  • This report provides a comprehensive study of the global market for neurostimulation technologies and devices.
  • It provides a detailed description of the different types of neurostimulation technologies and devices (invasive and noninvasive) and their current and historical market revenues.
  • Currently, the potential of neurostimulation technology is actively being explored for other clinical conditions including obesity, tinnitus and central nerve system disorders.
  • An in-depth analysis of the global market for neurostimulation technologies and devices includes historical data and market projections by device type, therapeutic application and region.

Tivic Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Medical Devices, Biometrics, Health, Health Technology, HCP, Telephone, Security (finance), Vagus nerve stimulation, Bank statement, Northwell Health, Medical research, Partnership, Pain, System, Video game, Health care, Cryptocurrency, Webcast

Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 (“Q3 2023”).

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 (“Q3 2023”).
  • Revenue for Q3 2023 was $282 thousand, compared to $161 thousand for Q2 2023 and $477 thousand in Q3 2022.
  • Total operating expenses were $1.9 million for the third quarter 2023, compared to $2.6 million in the same period 2022.
  • Management will host a webcast/conference call on Tuesday, November 14, 2023 at 1:30 PM PT / 4:30 PM ET to discuss the company’s third quarter 2023 financial results and provide a business update.

Feinstein Institutes’ Dr. Kevin J. Tracey receives 2023 Hans Wigzell Research Foundation's Science Prize

Retrieved on: 
Thursday, November 2, 2023
Science, Health, Neurology, Research, Sequence, Feinstein Institutes for Medical Research, Inflammation, Karolinska Institute, Doctor of Philosophy, Rheumatoid arthritis, Biomedical sciences, Shock, Immunity, Neuroscience, Boston University, Neurosurgery, Death, Rockefeller University, Medical research, Hope, Nobel Committee, Vagus nerve stimulation, Reflex, Cytokine, Boston College, Royal Academies for Science and the Arts of Belgium, Northwell Health, Medicine, Credit, UNESCO Science Prize, Patient, Vagus nerve, Septic shock, Human, University Medical Center, BS, Laboratory, Travel, Olivia Wigzell, Chemistry, Survival, Education, Royal Academy of Arts, Water, Multimedia, Dana, Engineering, Rockefeller, Student, Dana Foundation, Sepsis, Inflammatory bowel disease, Nursing, Pharmaceutical industry, Medical device, MD

The Hans Wigzell Research Foundation today announced that Kevin J. Tracey, MD, president and CEO of Northwell Health’s Feinstein Institutes for Medical Research , is the recipient of the 2023 Hans Wigzell Research Foundation’s Science Prize in recognition of his significant contributions to the fields of neuroscience and neuroimmunology.

Key Points: 
  • The Hans Wigzell Research Foundation today announced that Kevin J. Tracey, MD, president and CEO of Northwell Health’s Feinstein Institutes for Medical Research , is the recipient of the 2023 Hans Wigzell Research Foundation’s Science Prize in recognition of his significant contributions to the fields of neuroscience and neuroimmunology.
  • Dr. Tracey will travel to Stockholm, Sweden, to receive the prize, which includes $100,000, and deliver a lecture on December 1.
  • View the full release here: https://www.businesswire.com/news/home/20231102553265/en/
    Dr. Kevin J. Tracey has been named awardee of the 2023 Hans Wigzell Research Foundation's Science Prize.
  • “The prize is given to Dr. Tracey for his innovative discoveries of the mechanisms of how nerves transmit signals to stop inflammatory diseases,” said Hans Wigzell, MD, PhD, on behalf of the Hans Wigzell Research Foundation.